From 1996

Dr Farinelli and Dr Pascal Mayer co-invented the DNA colonies, a massively parallel DNA sequencing technology. This technology is the key of illumina NGS technology and used on MiSeq, NextSeq, HiSeq or NovaSeq instruments.

From 2003

The company Fasteris SA was founded by Laurent Farinelli and Magne Osteras, at that time servicing Sanger DNA sequencing.

From 2007

Fasteris SA was the first service company in the world to acquire an illumina NGS instrument, the Solexa Genome Analyzer.

From 2012

Fasteris participated in the development of Prendia, the first European non-invasive prenatal test launched in March 2013. This project led by Dr. Bernard Conrad was a fruitful collaboration between Genesupport, the SIB Swiss Institute of Bioinformatics and Fasteris.

From 2013

Fasteris joined the Medisupport network of laboratories. Our strategy is to expand into medical analyses thanks to our new partnership: Fasteris provides the expertise in NGS DNA sequencing and Medisupport the access to patients and doctors in a regulated environment.

Mid-2015

Medisupport was acquired by Sonic Healthcare, a publicly traded Australian company sharing our values: "Sonic Healthcare is an international healthcare company focused on delivering quality, independent services in medical diagnostics and multidisciplinary medical practices".

From 2015

Fasteris smoothly achieved ISO9001:2008 certification, as the company was already using management systems resulting in a "quality-oriented" culture. This certification is important to show our partners and customers that we are dedicated to continuous improvement in all our services, from the researchers who often require customized services and development of new applications to the pharma and medical laboratories who require highly regulated and process-oriented services.

Simultaneously, Medisupport increased its ownership of Fasteris SA shares to 100%. Along with the administrative changes, there is no principle change of Fasteris services, the same scientific and administrative team remains in charge for all of our Life Science services.

From 2017

Fasteris obtained Swiss federal authorization for genetics; ISO 17025:2005 & ISO 15189:2012 accreditation and the specific federal authorization for Preimplantation Genetic Testing for Aneuploidy (PGT-A). We were the first laboratory in Switzerland, in collaboration with our sister laboratory Fertas, to launch NGS-based PGT-A.

Fasteris has always been active on the worldwide NGS market and Sonic Heathcare brings new medical opportunities for Fasteris. On the other hand, Fasteris and Medisupport provide Sonic with the excellent expertise of NGS service provider associated with medical analyses and medical know-how.

Merge of Fasteris and Genesupport. In 2020, Geneva-based Fasteris and its sister laboratory Lausanne-based Genesupport merged into a single company.

Life Science services to researchers continue to be provided under the brand name Fasteris. Fasteris is one of the world's leading biotechnology company, continuously developing a wide range of applications and services in the areas of Next-Generation (NGS) and Sanger sequencing.

• The administrative changes are described as a letter to our partners.

• Geneva Trade Register records are available here.

Fasteris | LifeScience provider for NGS and Sanger services